[go: up one dir, main page]

AU2002230869A1 - Antisense modulation of hepsin expression - Google Patents

Antisense modulation of hepsin expression

Info

Publication number
AU2002230869A1
AU2002230869A1 AU2002230869A AU3086902A AU2002230869A1 AU 2002230869 A1 AU2002230869 A1 AU 2002230869A1 AU 2002230869 A AU2002230869 A AU 2002230869A AU 3086902 A AU3086902 A AU 3086902A AU 2002230869 A1 AU2002230869 A1 AU 2002230869A1
Authority
AU
Australia
Prior art keywords
antisense modulation
hepsin expression
hepsin
expression
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002230869A
Inventor
Lex M Cowsert
Patrick Allen Marcotte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Ionis Pharmaceuticals Inc
Original Assignee
Abbott Laboratories
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories, Isis Pharmaceuticals Inc filed Critical Abbott Laboratories
Publication of AU2002230869A1 publication Critical patent/AU2002230869A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • C12N2310/334Modified C
    • C12N2310/33415-Methylcytosine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/341Gapmers, i.e. of the type ===---===
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/346Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002230869A 2000-12-20 2001-12-14 Antisense modulation of hepsin expression Abandoned AU2002230869A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/742,703 US6423543B1 (en) 2000-12-20 2000-12-20 Antisense modulation of hepsin expression
US09/742,703 2000-12-20
PCT/US2001/048431 WO2002050248A2 (en) 2000-12-20 2001-12-14 Antisense modulation of hepsin expression

Publications (1)

Publication Number Publication Date
AU2002230869A1 true AU2002230869A1 (en) 2002-07-01

Family

ID=24985879

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002230869A Abandoned AU2002230869A1 (en) 2000-12-20 2001-12-14 Antisense modulation of hepsin expression

Country Status (3)

Country Link
US (1) US6423543B1 (en)
AU (1) AU2002230869A1 (en)
WO (1) WO2002050248A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016484A2 (en) * 2001-08-17 2003-02-27 Affymetrix, Inc. Gleason grade 4/5 prostate cancer genes
US20040029151A1 (en) * 2002-04-09 2004-02-12 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
US20050272052A1 (en) * 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
WO2004086035A1 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with hepsin (hpn)
US7029675B1 (en) 2003-06-04 2006-04-18 Shu-Wha Lin Hepsin antagonist and methods of use
MX2007001064A (en) * 2004-07-26 2007-04-12 Genentech Inc Methods and compositions for modulating hepatocyte growth factor activation.
EP2462937A1 (en) * 2005-05-24 2012-06-13 Isis Pharmaceuticals, Inc. Modulation of LMW-PTPase Expression
AU2007260953B2 (en) * 2006-06-22 2013-07-11 Genentech, Inc. Methods and compositions for modulating hepsin activation of urokinase-type plasminogen activator
CA2656168A1 (en) 2006-06-22 2007-12-27 Genentech, Inc. Methods and compositions for targeting hepsin
US20100280139A1 (en) * 2009-04-30 2010-11-04 Bayer Materialscience Llc Sprayable elastomeric polyurethane foam and process for its production
US20100279101A1 (en) * 2009-04-30 2010-11-04 Bayer Materialscience Llc Composites produced from sprayable elastomeric polyurethane foam
WO2017162659A1 (en) 2016-03-24 2017-09-28 Bayer Pharma Aktiengesellschaft Intracellular hepsin as therapeutic target for the treatment of cancer with centrosome amplification

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981830A (en) * 1997-05-30 1999-11-09 Schering Aktiengesellschaft Knockout mice and their progeny with a disrupted hepsin gene

Also Published As

Publication number Publication date
WO2002050248A2 (en) 2002-06-27
WO2002050248A3 (en) 2003-01-03
US6423543B1 (en) 2002-07-23

Similar Documents

Publication Publication Date Title
AU2001289085A1 (en) Antisense modulation of flip-c expression
AU2001294926A1 (en) Antisense modulation of smad6 expression
AU2001277054A1 (en) Antisense modulation of lysophospholipase i expression
AU2212600A (en) Antisense modulation of g-alpha-i1 expression
AU6296099A (en) Antisense modulation of g-alpha-12 expression
AU2002309819A1 (en) Antisense modulation of PTP1B expression
AU2001261808A1 (en) Antisense modulation of pten expression
AU2001289046A1 (en) Antisense modulation of her-2 expression
AU2001229447A1 (en) Antisense modulation of smad7 expression
AU5788599A (en) Antisense modulation of interleukin-15 expression
AU2001278077A1 (en) Antisense modulation of ptp1b expression
AU2001239971A1 (en) Antisense modulation of parp expression
AU2001227847A1 (en) Antisense modulation of pepck-cytosolic expression
AU6115400A (en) Antisense modulation of mekk5 expression
AU2002230869A1 (en) Antisense modulation of hepsin expression
AU2002366788A1 (en) Antisense modulation of ship-1 expression
AU2001288968A1 (en) Antisense modulation of btak expression
AU2002318139A1 (en) Antisense modulation of src-c expression
AU2209000A (en) Antisense modulation of pepck-mitochondrial expression
AU2002226064A1 (en) Antisense modulation of talin expression
AU5486700A (en) Antisense modulation of g-alpha-s1 expression
AU2002357102A1 (en) Antisense modulation of cd36l1 expression
AU2001287136A1 (en) Antisense modulation of glioma-associated oncogene-1 expression
AU2410600A (en) Antisense modulation of g-alpha-i3 expression
AU2001296731A1 (en) Antisense modulation of bcas1 expression